Day: September 17, 2025

LAKEWOOD, NJ, Sept. 17, 2025 (GLOBE NEWSWIRE) — Reliance Global Group, Inc. (Nasdaq: RELI) (“Reliance”, “we” or the “Company”) today announced that it has completed its first digital asset purchase under its recently launched Digital Asset Treasury (“DAT”) initiative, acquiring Ethereum (ETH). The purchase represents the initial step in Reliance’s broader plan to build a diversified digital asset portfolio, with future investments expected to include leading cryptocurrencies such as Bitcoin, Ethereum and Solana. The Company plans to fund these activities through a combination of cash reserves and other approved corporate financing tools. Reliance’s DAT initiative is structured to pursue long-term capital appreciation through blockchain-based participation. As part of this strategy, Reliance has also formed a dedicated Crypto Advisory...

Nylon and Polyester Are Polluting the Planet with Microplastics DENVER, Sept. 17, 2025 (GLOBE NEWSWIRE) — 247marketnews.com, a pioneer in digital media dedicated to the swift distribution of financial market news and information, today spotlights a major environmental threat that Kraig Biocraft Laboratories (OTCQB: KBLB), the undisputed global leader in the development and commercialization of spider silk, is ideally positioned to address. Spider silk technology offers a biodegradable, plastic-free alternative to nylon and polyester fibers, which are major generators of microplastics, as regulators and eco-conscious brands pivot away from “fossil-based” textiles. Microplastics from Synthetic Fibers Are Choking the Planet Nylon and polyester, two of the most widely used materials in global apparel production, are petroleum-derived...

WESTBROOK, Maine, Sept. 17, 2025 (GLOBE NEWSWIRE) — Synergy CHC Corp. (NASDAQ: SNYR), a leading consumer health and wellness company, today announced a strategic distribution partnership with AlaBev, one of the Southeast’s premier beverage distributors, to expand retail availability of its flagship FOCUSfactor® Focus + Energy functional beverage line and brain-health energy shots. Under this agreement, AlaBev will distribute FOCUSfactor products to more than 5,000 grocery, convenience, and specialty retailers across Alabama, making the clinically supported cognitive performance brand widely accessible to consumers seeking clean, science-backed energy and focus solutions. AlaBev: A Century of Distribution Strength With nearly 120 years of experience and three strategically located warehouses, AlaBev has built a reputation as a trusted...

VENU Leverages Early $55M Raise Into $1.3B Pipeline, Adds $45M for Next Phase DENVER, Sept. 17, 2025 (GLOBE NEWSWIRE) — 247marketnews.com, a pioneer in digital media dedicated to the swift distribution of financial market news and corporate information, reports that recent capital raises position VENU (NYSE American: VENU) with more than $45 million to allocate toward new amphitheater projects. When VENU first went public, the company raised approximately $55 million through its initial equity financings, from a $32 million private placement, IPO proceeds, and private investor funds. Management has treated those funds as impact capital, leveraging it into more than $1.3 billion in ongoing construction. That’s a better than 23-to-1 return in asset creation in under a year, underscoring the efficiency of VENU’s model. The most recent...

HilleVax Stockholders Received $1.95 Per Share in Cash Plus a Contingent Value Right EMERYVILLE, Calif., Sept. 17, 2025 (GLOBE NEWSWIRE) — XOMA Royalty Corporation (NASDAQ: XOMA) (“XOMA Royalty” or the “Company”), a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health, today announced the Company has successfully completed its previously announced tender offer to acquire all outstanding shares of HilleVax, Inc. (NASDAQ: HLVX) (“HilleVax”) common stock for a price per share of $1.95 in cash (the “Cash Amount”), plus one non-tradeable contingent value right (“CVR” and together with the Cash Amount, the “Offer Price”). The tender offer and related withdrawal rights expired one minute after 11:59 p.m. Eastern Time on Monday, September 15, 2025 (the “Expiration...

PALI-2108 demonstrated favorable safety, with no serious adverse events, lab abnormalities, or EKG concerns Phase 1b data demonstrated 100% clinical response and promising signals regarding the efficacy of PALI-2108 in ulcerative colitis (UC) using FDA-defined endpoints Biomarker analyses showed normalization of 186 genes linked to fibrosis and Crohn’s disease strictures, supporting translational potential in fibrostenotic Crohn’s disease (FSCD) Patient dosing in the Phase 1b FSCD study is expected to begin in 2H 2025; Phase 2 IND submissions anticipated in 1H 2026 Carlsbad, CA, Sept. 17, 2025 (GLOBE NEWSWIRE) — Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade,” “Palisade Bio,” or the “Company”), a clinical-stage biopharmaceutical company developing precision therapies for autoimmune, inflammatory, and fibrotic diseases, today announced...